Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Gross Margin (2016 - 2025)

Historic Gross Margin for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to 70.28%.

  • Cytosorbents' Gross Margin rose 92600.0% to 70.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 70.8%, marking a year-over-year increase of 26100.0%. This contributed to the annual value of 70.59% for FY2024, which is 300.0% down from last year.
  • As of Q3 2025, Cytosorbents' Gross Margin stood at 70.28%, which was up 92600.0% from 70.85% recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Gross Margin ranged from a high of 77.46% in Q2 2021 and a low of 44.6% during Q3 2022
  • For the 5-year period, Cytosorbents' Gross Margin averaged around 67.16%, with its median value being 70.85% (2025).
  • Per our database at Business Quant, Cytosorbents' Gross Margin crashed by -301700bps in 2022 and then skyrocketed by 190400bps in 2023.
  • Quarter analysis of 5 years shows Cytosorbents' Gross Margin stood at 71.04% in 2021, then decreased by -14bps to 61.31% in 2022, then fell by 0bps to 61.27% in 2023, then rose by 16bps to 70.97% in 2024, then dropped by -1bps to 70.28% in 2025.
  • Its Gross Margin was 70.28% in Q3 2025, compared to 70.85% in Q2 2025 and 71.13% in Q1 2025.